Physician profile
Rafael Contreras
NPI 1750930368
$1,408.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $318 · 2023: $163 · 2024: $79.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $174.04 | 2021-2023 | Lybalvi |
| Abbvie INC. | $163.49 | 2021-2023 | |
| Corium, LLC | $121.10 | 2022-2024 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $116.42 | 2021-2022 | |
| Neos Therapeutics, LP | $100.69 | 2021-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $100.29 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $94.44 | 2021 | |
| Neurocrine Biosciences, INC. | $84.10 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $58.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $55.19 | 2021-2023 | Uzedy |
| Supernus Pharmaceuticals, INC. | $53.57 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $53.42 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.03 | 2021 | |
| Tris Pharma INC | $42.74 | 2022-2023 | Dyanavel Xr |
| Indivior INC. | $33.07 | 2024 | Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.16 | 2022 | |
| Bausch Health US, LLC | $14.92 | 2021 | |
| Lundbeck LLC | $14.44 | 2021 | |
| Owp Pharmaceuticals, INC. | $13.97 | 2021 | |
| Almatica Pharma LLC | $13.45 | 2022 | |
| Aytu Biopharma, INC. | $13.30 | 2021 | |
| Adlon Therapeutics L.P. | $13.12 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.